Compounds > moxifloxacin
Page last updated: 2024-09-04

moxifloxacin and cilomilast

moxifloxacin has been researched along with cilomilast in 3 studies

Compound Research Comparison

Studies
(moxifloxacin)		Trials
(moxifloxacin)		Recent Studies (post-2010)
(moxifloxacin)		Studies
(cilomilast)		Trials
(cilomilast)		Recent Studies (post-2010) (cilomilast)
3,1575521,6901621342

Protein Interaction Comparison

ProteinTaxonomymoxifloxacin (IC50)cilomilast (IC50)
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.018
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.018
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.018
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.018
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.018
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.018
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.018
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.018
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.018
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.018
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.018
Chain B, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.018
Chain A, cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.018
Chain A, cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.018
cGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)2.3453
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)2.3453
cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)2.3453
cAMP-specific 3',5'-cyclic phosphodiesterase 4D Rattus norvegicus (Norway rat)0.113
cAMP-specific 3',5'-cyclic phosphodiesterase 4CRattus norvegicus (Norway rat)0.113
cAMP-specific 3',5'-cyclic phosphodiesterase 4BRattus norvegicus (Norway rat)0.1623
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)0.3113
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)0.062
cAMP-specific 3',5'-cyclic phosphodiesterase 4ARattus norvegicus (Norway rat)0.113
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)2.3453
cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.4623
cAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)0.818
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.4642
cGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)4.259
cGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)10
Beta-2 adrenergic receptorCavia porcellus (domestic guinea pig)0.12
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11AHomo sapiens (human)2.3453
cAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)2.3453
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)2.3453

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1

Other Studies

3 other study(ies) available for moxifloxacin and cilomilast

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010